Insmed: HC Wainwright Raises PT to $240 from $120, Maintains Buy Rating

Insmed: HC Wainwright Raises PT to $240 from $120, Maintains Buy Rating

H.C. Wainwright analyst Andrew Fein has raised the price target for Insmed Incorporated (NASDAQ: INSM) to $240 from $120, while maintaining a Buy rating on the company. This significant adjustment comes following the release of Insmed's Q2 2025 earnings report, which showed a net loss of $322 million but a 68% surge in share price over the past quarter.

The company reported ARIKAYCE revenue of $107.4 million, a 19% increase year-over-year, surpassing analyst estimates of $103.03 million. Strong performance in the U.S. market and impressive growth in international markets, particularly Japan and Europe, contributed to this revenue growth. Additionally, the company's late-stage pipeline developments, including the U.S. launch of brensocatib for non-cystic fibrosis bronchiectasis (NCFB) scheduled for Q3 2025 and promising results from the Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) in pulmonary arterial hypertension (PAH), have bolstered investor confidence.

However, Insmed's operating expenses increased significantly, leading to a widened operating loss. R&D expenses rose to $177.2 million, and SG&A expenses jumped to $154.8 million. Despite these increased investments, the company maintains a robust capital position with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of June 30, 2025.

Insider sentiment remains negative, with an increase in insiders selling their shares. Despite this, investors remain optimistic about Insmed's future prospects, with the company's total return of 308.60% over three years. The upcoming launch of brensocatib in the U.S. and favorable market response to ARIKAYCE are expected to bolster revenue projections.

References:
[1] https://www.investing.com/news/company-news/insmed-q2-2025-slides-reveal-19-revenue-growth-amid-clinical-pipeline-advances-93CH-4176654
[2] https://www.marketbeat.com/instant-alerts/insmed-nasdaqinsm-hits-new-1-year-high-heres-what-happened-2025-08-05/